| Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy SJ Priceman, JL Sung, Z Shaposhnik, JB Burton, AX Torres-Collado, ... Blood, The Journal of the American Society of Hematology 115 (7), 1461-1471, 2010 | 412 | 2010 |
| Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy CK Domigan, CM Warren, V Antanesian, K Happel, S Ziyad, S Lee, ... Journal of cell science 128 (12), 2236-2248, 2015 | 177 | 2015 |
| Cleavage of syndecan-4 by ADAMTS1 provokes defects in adhesion JC Rodríguez-Manzaneque, D Carpizo, M del Carmen Plaza-Calonge, ... The international journal of biochemistry & cell biology 41 (4), 800-810, 2009 | 97 | 2009 |
| ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2 AX Torres-Collado, W Kisiel, ML Iruela-Arispe, ... Journal of Biological Chemistry 281 (26), 17827-17837, 2006 | 78 | 2006 |
| Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis C Stockmann, Y Kerdiles, M Nomaksteinsky, A Weidemann, N Takeda, ... Proceedings of the National Academy of Sciences 107 (9), 4329-4334, 2010 | 76 | 2010 |
| Variable inhibition of thrombospondin 1 against liver and lung metastases through differential activation of metalloproteinase ADAMTS1 YJ Lee, M Koch, D Karl, AX Torres-Collado, NT Fernando, C Rothrock, ... Cancer research 70 (3), 948-956, 2010 | 74 | 2010 |
| ADAMTS1 contributes to the acquisition of an endothelial-like phenotype in plastic tumor cells C Casal, AX Torres-Collado, MC Plaza-Calonge, E Martino-Echarri, ... Cancer research 70 (11), 4676-4686, 2010 | 56 | 2010 |
| Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor) AX Torres-Collado, J Knott, AR Jazirehi Cancers 10 (6), 157, 2018 | 48 | 2018 |
| Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen‐1 and nidogen‐2 E Martino‐Echarri, R Fernández‐Rodríguez, FJ Rodríguez‐Baena, ... International journal of cancer 133 (10), 2315-2324, 2013 | 44 | 2013 |
| Overcoming resistance of human non-Hodgkin’s lymphoma to CD19-CAR CTL therapy by celecoxib and histone deacetylase inhibitors AX Torres-Collado, AR Jazirehi Cancers 10 (6), 200, 2018 | 41 | 2018 |
| Aberrant apoptotic machinery confers melanoma dual resistance to BRAFV600E inhibitor and immune effector cells: Immunosensitization by a histone deacetylase inhibitor AR Jazirehi, R Nazarian, AX Torres-Collado, JS Economou American journal of clinical and experimental immunology 3 (1), 43, 2014 | 39 | 2014 |
| Selective decline of synaptic protein levels in the frontal cortex of female mice deficient in the extracellular metalloproteinase ADAMTS1 MD Howell, AX Torres-Collado, ML Iruela-Arispe, PE Gottschall Public Library of Science 7 (10), e47226, 2012 | 25 | 2012 |
| Anti‐tRNP(ser)sec/SLA/LP autoantibodies. Comparative study using in‐house ELISA with a recombinant 48.8 kDa protein, immunoblot, and analysis of … AX Torres‐Collado, AJ Czaja, C Gelpí Liver International 25 (2), 410-419, 2005 | 22 | 2005 |
| Rescue of cell cycle progression in BRAFV600E inhibitor–resistant human melanoma by a chromatin modifier AX Torres-Collado, R Nazarian, AR Jazirehi Tumor Biology 39 (9), 1010428317721620, 2017 | 10 | 2017 |
| Epigenetic regulation of melanoma tumor suppressor miRNA-124a AR Jazirehi, AX Torres-Collado, R Nazarian Epigenomics 5 (3), 251-252, 2013 | 8 | 2013 |
| Role of miR-18b/MDM2/p53 circuitry in melanoma progression. AR Jazirehi, AX Torres-Collado, R Nazarian Epigenomics 5 (3), 254-254, 2013 | 6 | 2013 |
| Circumvention of drug-resistance via decitabine-mediated DNMT1 depletion. AX Torres-Collado, AR Jazirehi Epigenomics 5 (3), 253-254, 2013 | 1 | 2013 |
| Contribution of ADAMs and ADAMTSs to tumor expansion and metastasis AX Torres-Collado, ML Iruela-Arispe Cancer Genome and Tumor Microenvironment, 293-314, 2010 | 1 | 2010 |
| Abstract C143: Overcoming melanoma dual resistance to Vemurafenib and adoptive immunotherapy by chromatin remodeling drug. AR Jazirehi, R Nazarian, AJ Toress-Collado, JS Economou Molecular Cancer Therapeutics 12 (11_Supplement), C143-C143, 2013 | | 2013 |
| Epigenetic fine-tuning of NF-κB-Sox9 circuitry in cancer stem cells. AR Jazirehi, AX Torres-Collado Epigenomics 5 (4), 363-364, 2013 | | 2013 |
M. Luisa Iruela-ArispeProfessor and Chair Dept. Cell & Dev. BiologyVerified email at northwestern.edu
